A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease

Summary

The main purpose of this study is to investigate the safety and efficacy of the study drug solanezumab in participants with prodromal Alzheimer's disease (AD).

Timeline

Start

2016-06

Primary completion

2017-05

Completion

2017-05

Outcome

Outcome not reported

Stopped: “Insufficient scientific evidence that solanezumab would likely demonstrate a meaningful benefit to participants with prodromal AD as defined by study protocol.”

Drugs

Indications